Overview

A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy

Status:
Completed
Trial end date:
2001-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and clinical utility of Duragesic® 12.5 micrograms/hour (a transdermal patch delivering the narcotic pain-reliever fentanyl) in the treatment of children ages 2 to 12 with continuous pain requiring narcotic pain relief therapy. Pharmacokinetics (fentanyl levels in the bloodstream during treatment) will also be assessed.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium
Treatments:
Fentanyl